Single ketamine infusion in bipolar depression resistant to antidepressants: Are neurotrophins involved?

Human Psychopharmacology

Volumn 28, Issue 1, 2013, Pages 87-90

  Rybakowski, Janusz K ^a   Permoda Osip, Agnieszka ^a   Skibinska, Maria ^a   Adamski, Rafal ^a   Bartkowska Sniatkowska, Alicja ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

BDNF; bipolar depression; GDNF; ketamine; NGF; NT3; NT4

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; KETAMINE; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4;

ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; TREATMENT OUTCOME;

EID: 84873871165     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2271     Document Type: Article

References (19)

1. Autry AE, Adach M, Nosyreva E, et al,. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
2. Covvey JR, Crawford AN, Lowe DK,. 2012. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother 46: 117-23.
3. De Sousa RT, Van de Bilt MT, Diniz BS, et al,. 2011. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494: 54-56.
4. Diazgranados N, Ibrahim L, Brutsche NE, et al,. 2010. A randomized add-on trial of an N-methyl- d -aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
5. First MB, Spitzer RL, Gibbon M, Williams J,. 1996. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press Inc.: Washington, D.C.
6. Garcia LS, Comim CM, Valvassori SS, et al,. 2008. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32: 140-144.
7. Garcia LS, Comim CM, Valvassori SS, et al,. 2009. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 450-455.
8. Lindholm JS, Autio H, Vesa L, et al,. 2012. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf +/- heterozygous null mice. Neuropharmacology 62: 391-397.
9. Machado-Vieira R, Yuan P, Brutsche N, et al,. 2009. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl- d -aspartate antagonist. J Clin Psychiatry 70: 1662-1666.
10. Molendijk ML, Bus BA, Spinhoven P, et al,. 2011. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16: 1088-1095.
11. Permoda-Osip A, Adamski R, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Skibinska M, Rybakowski JK,. 2011. Efficacy of single ketamine infusion in bipolar depression: relationship with serum BDNF. Eur Neuropsychopharmacol 21 (Suppl 3): S428.
12. Price RB, Nock MK, Charney DS, Mathew SJ,. 2009. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522-526.
13. Rybakowski JK,. 2007. Two generations of mood stabilizers. Int J Neuropsychopharmacol 10: 709-711.
14. Rybakowski JK, Suwalska A,. 2010. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 13: 617-622.
15. Yoshimura R, Tsuji K, Ueda N, Nakamura J,. 2007. Increase of plasma brain-derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment. Neuropsychiatr Dis Treatm 3: 683-686.
16. Yoshimura R, Ikenouschi-Sugita A, Hori H, et al,. 2010. Adding an atypical antipsychotic drug induced a rapid increase of plasma BDNF levels in refractory depression. Eur Neuropsychopharmacol 20 (Suppl. 3): S367.
17. Yoshimura R, Hori H, Ikenouschi-Sugita A, et al,. 2012. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 27: 33-38.
18. Zarate CA Jr, Singh JB, Carlton PJ, et al,. 2006. A randomized trial of an N-methyl- d -aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
19. Zarate CA Jr, Brutsche NE, Ibrahim L, et al,. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71 (11): 939-946.